A Phase 1 interventional study of Olaparib tablets, 150 mg and Lynparza® (olaparib) tablets 150 mg in Ovarian Cancer and Breast Cancer, sponsored by Sandoz. Completed at 1 site in India. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by Sandoz (formerly part of Novartis) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.
Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 39th largest by enrollment, is one of 3 that started in 2022, is one of 15 in phase 1, and was the 56th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Bai-Rong Xia · Sites in China
Ages 18–75 · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+ · Women only
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19–74 · Women only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
NRG Oncology · Sites in United States, Japan, Puerto Rico
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 17 · Phase 4 3
First in 2005; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 97 across the 69 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
23 studies in Ovarian Neoplasms by Novartis: none open now, 1 under way, none of them phase 3. Of 22 finished, 8 (36%) have results posted.
Among the 23 studies in Ovarian Neoplasms by Novartis, this one is the 12th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2022, is one of 10 in phase 1, and was the 21st registered.
Novartis’s Ovarian Neoplasms studies by the year they started, since 1997.
5 of the studies testing olaparib in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT07371104Daewoong Pharmaceutical Co. LTD.Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | 2027-03 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03943173M.D. Anderson Cancer CenterOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | 2027-06-27 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies testing olaparib in Ovarian Neoplasms, from their registry updates:
Among Novartis’s 23 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a two-way crossover bioequivalence study between test and reference product in patients diagnosed with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.
This is a two-way crossover bioequivalence study between test and reference product in patients diagnosed with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.
Patients will be enrolled after providing written informed consent and treatments will be allocated to patient by carrying out randomization using statistical techniques.
Patients that are already on a stable dose of Lynparza® (olaparib) tablets and have met the eligibility criteria will be directly randomized for participation in the study.
After randomization patients will receive either test or reference product in a crossover manner based on the randomization schedule. Patients will receive the dose of 300 mg twice daily for 16 days in a crossover design.
In period-I (Day 1 to Day 8), patients will receive either Test product or Reference product for 8 days based on the randomization schedule.
In period-II (Day 9 to Day 16), patients will be switched to the other product for a second period of 8 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
OR Maintenance Treatment of Recurrent Ovarian Cancer maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
OR Advanced Germline BRCA-mutated Ovarian Cancer After 3 or More Lines of Chemotherapy treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
OR Germline BRCA-mutated Human epidermal growth factor receptor 2 () -negative Breast Cancer treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the , adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.
OR Women of child bearing potential must have negative pregnancy test at screening visit and before randomization and must agree to use an effective method of avoiding pregnancy (including oral, transdermal or implanted [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to IMP administration] sexual partner) for at least 4 weeks prior to IMP administration, during the study and up to 6 months after the last dose of IMP. Cessation of birth control after this point should be discussed with a responsible physician.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design
Drug: Olaparib tablets, 150 mg · Drug: Lynparza® (olaparib) tablets 150 mg
participants will receive 2 x 150 mg Olaparib tablets twice daily for 16 days in a crossover design
Drug: Olaparib tablets, 150 mg · Drug: Lynparza® (olaparib) tablets 150 mg
Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia
Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (DE).
Maximum Plasma Concentration During the Dosing Interval at Steady State (CmaxSS)
To assess the pharmacokinetics and establish bioequivalence of the Test Product (Olaparib tablets, 150 mg) relative to that of Reference Product (Lynparza® (olaparib) tablets 150 mg) in patients with Breast Cancer Gene (BRCA) mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.
Time frame: Pre-dose (0.00 hr) on day 1,6,7,8,14,15 and 16 and Post-dose on day 8 and day 16
Area Under the Plasma Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-t)ss)
To assess the pharmacokinetics and establish bioequivalence of the Test Product (Olaparib tablets, 150 mg) relative to that of Reference Product (Lynparza® (olaparib) tablets 150 mg) in patients with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.
Time frame: Pre-dose (0.00 hr) on day 1,6,7,8,14,15 and 16 and Post-dose on day 8 and day 16
Number of Serious Adverse Events
To monitor the serious adverse events of patients and to assess safety of each of the two formulations.
Time frame: up to Day 24
Number of Adverse Events
To monitor the adverse events of patients and to assess safety of each of the two formulations.
Time frame: up to Day 24
| Milestone | Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mg | Lynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mg |
|---|---|---|
| Started | 35 | 35 |
| Completed | 35 | 35 |
| Not completed | 0 | 0 |
| Milestone | Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mg | Lynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mg |
|---|---|---|
| Started | 35 | 35 |
| Completed | 34 | 35 |
| Not completed | 1 | 0 |
To assess the pharmacokinetics and establish bioequivalence of the Test Product (Olaparib tablets, 150 mg) relative to that of Reference Product (Lynparza® (olaparib) tablets 150 mg) in patients with Breast Cancer Gene (BRCA) mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.
| ng/mL | Olaparib Tablets, 150 mg | Lynparza® (Olaparib) Tablets 150 mg |
|---|---|---|
| Maximum Plasma Concentration During the Dosing Interval at Steady State (CmaxSS) | 10395.085 ± 3374.4800 | 9676.278 ± 2845.1708 |
To assess the pharmacokinetics and establish bioequivalence of the Test Product (Olaparib tablets, 150 mg) relative to that of Reference Product (Lynparza® (olaparib) tablets 150 mg) in patients with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.
| hr*ng/mL | Olaparib Tablets, 150 mg | Lynparza® (Olaparib) Tablets 150 mg |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-t)ss) | 59480.137 ± 25073.7016 | 64104.218 ± 29492.0018 |
To monitor the serious adverse events of patients and to assess safety of each of the two formulations.
| Number of Serious Adverse Events | Olaparib Tablets, 150 mg | Lynparza® (Olaparib) Tablets 150 mg |
|---|---|---|
| Number of Serious Adverse Events | 0 | 1 |
To monitor the adverse events of patients and to assess safety of each of the two formulations.
| Number of Adverse Events | Olaparib Tablets, 150 mg | Lynparza® (Olaparib) Tablets 150 mg |
|---|---|---|
| Number of Adverse Events | 43 | 37 |
Collected over From signing informed consent form till end of the study safety assessments (24 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib Tablets, 150 mg | 0/70 (0%) | 0/70 (0%) | 19/70 (27.1%) |
| Lynparza® (Olaparib) Tablets 150 mg | 0/69 (0%) | 1/69 (1.4%) | 17/69 (24.6%) |
| Event | Olaparib Tablets, 150 mg | Lynparza® (Olaparib) Tablets 150 mg |
|---|---|---|
| AstheniaGeneral disorders | 0/70 | 1/69 |
| Event | Olaparib Tablets, 150 mg | Lynparza® (Olaparib) Tablets 150 mg |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 7/70 | 7/69 |
| NauseaGastrointestinal disorders | 6/70 | 4/69 |
| White blood cell count decreasedInvestigations | 2/70 | 4/69 |
| AstheniaGeneral disorders | 4/70 | 2/69 |
| Age, Continuous(years) | Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mg | Lynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mg | Total |
|---|---|---|---|
| Mean | 47.77 ± 8.977 | 50.74 ± 10.590 | 49.26 ± 9.859 |
| Sex: Female, Male(Participants) | Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mg | Lynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mg | Total |
|---|---|---|---|
| Female | 35 | 35 | 70 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mg | Lynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 35 | 35 | 70 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mg | Lynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 35 | 35 | 70 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mg | Lynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mg | Total |
|---|---|---|---|
| India | 35 | 35 | 70 |
| BMI(Kg/m^2) | Olaparib Tablets, 150 mg, Then Lynparza® (Olaparib) Tablets 150 mg | Lynparza® (Olaparib) Tablets 150 mg, Then Olaparib Tablets, 150 mg | Total |
|---|---|---|---|
| Mean | 25.27 ± 3.480 | 25.62 ± 3.444 | 25.44 ± 3.441 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2022 to primary completion in Oct 2022, 6 months.
Results were first posted in Oct 2024, 1 year 11 months after primary completion.
Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 6 months is below that.
Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib